Please login to the form below
Isoniazid
This page shows the latest Isoniazid news and features for those working in and with pharma, biotech and healthcare.
Study shows Otsuka's TB drug works even in worst cases
The WHO defines XDR-TB as resistance to first-line drugs isoniazid and rifampicin, as well as resistance to at least one fluoroquinolone and another second-line injectable such as amikacin,
Latest news
-
Sanofi's Priftin cleared for latent tuberculosis in the US
After a priority review, the FDA has approved Priftin (rifapentine) in combination with isoniazid to treat latent TB infection in patients aged two years and older. ... weeks; the combination of rifampicin and isoniazid daily for 3-4 months; and
-
Researchers develop breath test for TB
Inhaled form of isoniazid could show almost instant results. Researchers have developed the first breath test to diagnose tuberculosis (TB). ... It uses an inhaled form of the antibiotic isoniazid that is activated by TB enzymes that are unique to the
-
Tuberculosis: treatment and prevention
Treatment and management of TB infection involves long-term administration of antibiotics, primarily rifampicin and isoniazid. ... Multi drug-resistant TB (MDR-TB) is defined as resistance to the gold standard treatment of isoniazid and rifampicin.
-
J&J gets EU green light for novel TB drug
In recent years, the burden of TB resistant to first-line therapy of at least isoniazid and rifampicin, the two major anti-tubercular treatments, has increased rapidly in the.
-
Janssen's Sirturo wins backing for conditional EU licence
In recent years, the burden of tuberculosis resistant to first-line therapy of at least isoniazid and rifampicin, the two major anti-tuberculosis treatments, has increased rapidly in the absence of
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
The fight against antimicrobial resistance
Isoniazid and rifampicin were effective against tuberculosis for decades, but today 3.7% of new cases and 20% of previously treated cases are believed to be caused by strains resistant to
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Could ketamine be the next big thing in depression?
Doctors noticed that tuberculosis patients treated with isoniazid showed signs of improved mood. ... Isoniazid is antituberclular but it also interferes with monoamine metabolism, slowing neurotransmitter breakdown once it is released.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
